AF atrial fibrillation
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - 18 years old or older - Patients with AF onset before 45 years old, reported by medical history or by documented ECG - Patients with AF onset between 45 and 60 years old, reported by medical history or by documented ECG AND at least one or more first or second-degree relatives who experienced AF before 60 years old, reported by medical history or by documented ECG - Suspected familial/genetic AF aetiology
Exclusion criteria
Exclusion criteria: A subject in whom clinical examination revealed the presence of (extra) cardiovascular disease associated with AF
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study is reached when a (likely) pathogenic variant has been identified. From this point on, routine clinical care resumes based on the findings of cardiovascular examination and genetic screening. | — |
Secondary
| Measure | Time frame |
|---|---|
| • To investigate the relation between genetic profiles and electrical (AF) phenotypes, including ECG parameters and electrical mapping studies. • To develop a specific gene panel for AF • To construct a blood biobank from (likely) pathogenic genetic variants carriers for iPSC generation and biomarker research. • To implement an AF specific gene screening in a dedicated outpatient clinic for patients with familial or young AF. • To unravel electromyopathy-related mechanistic pathways underlying familial or young AF. • To identify genetic targets for novel tailored therapy in genetic AF. | — |
Countries
Netherlands
Outcome results
None listed